Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Researchers have developed photoswitchable eye drops that restored light perception and visually guided behavior in blind mice — no implants, gene therapy, or specialized lighting needed. The compounds, called prosthe6, target surviving retinal neurons to mimic the function of lost photoreceptors. Two lead candidates worked via simple topical eye drop administration, raising hopes for a widely accessible treatment for degenerative blindness.
Scientists at the Institute for Bioengineering of Catalonia (IBEC) have developed a new class of light-activated, photoswitchable drugs — called prosthe6 — that restored meaningful visual function in animal models of blindness. Published in the Journal of the American Chemical Society, the study showed that blind mice regained their natural instinct to avoid bright light after receiving the treatment, indicating restored light perception and visually guided behavior.
The compounds work by targeting ON bipolar cells, retinal neurons that survive even after photoreceptors degenerate in diseases like age-related macular degeneration (AMD) and retinitis pigmentosa (RP). When light hits the eye, the molecules change shape and trigger visual signaling — essentially acting as "molecular prostheses" for the lost photoreceptors. Crucially, two lead compounds (prosthe6-12 and prosthe6-15) were effective under ordinary indoor and outdoor lighting levels, and worked when applied as simple eye drops.
By the Numbers:
Why it matters: Current vision-restoration options — gene therapy, retinal implants, optogenetics — are invasive, expensive, or limited to specific genetic mutations. A topical eye drop approach that works across different retinal disorders could be a game-changer for the millions with advanced degenerative blindness who currently have no effective treatment options.
